One of India’s Premier Maternal Care Specialists, Motherhood Hospitals, Standardizes on Masimo SET® Technology

MASI) announced today that Motherhood Hospitals, a maternal care
specialist with five hospitals in three cities in India, has
standardized on Masimo SET® (Signal Extraction
Technology) pulse oximetry at all locations. Motherhood Hospitals will
also be screening for Critical Congenital Heart Disease (CCHD) using
Masimo’s technology.

“We evaluated several technologies and found Masimo SET pulse oximetry
to be the most reliable even in the most challenging conditions,” said
Dr. Mohammed Rehan Sayeed, Chairman, Motherhood Hospitals. “This entire
standardization exercise was driven by the clinical staff.”

Masimo SET® Measure-through Motion and Low Perfusion™ pulse
oximetry measures oxygen saturation (SpO2), pulse rate (PR),
and perfusion index (PI), and helps clinicians monitor more than an
estimated 100 million patients a year.1 In a study of
newborns, researchers found CCHD was identified by physical examination
alone 63% of the time, and when Masimo SET® pulse oximetry
was added to the physical exam screening, researchers found that
clinicians were able to identify CCHD 83% of the time–a 31% increase.2

“We are happy to see the team at Motherhood Hospitals, which conducts
research into how to improve the health and well-being of neonates in
India, select our SET technology,” said Joe Kiani, Founder and CEO of
Masimo. “We hope to work with Motherhood Hospitals to standardize
universal screening for CCHD in newborns. We are seeing more and more
hospitals in this region of the world realize the important role
reliable pulse oximetry plays in patient care and safety.”

Motherhood Hospitals, a premium birthing boutique, provides a variety of
services to expecting women and newborns in India, specializing in
obstetrics, gynecology, neonatology, pediatrics, fetal medicine,
fertility, and cosmetology. At their combined locations in Bangalore,
Chennai, and Hyderabad, they perform over 6,000 deliveries annually.

@MasimoInnovates |

1 Masimo data on file.
2 de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C,
Inganäs L, Eriksson M, Segerdahl N, Agren A, Ekman-Joelsson BM,
Sunnegårdh J, Verdicchio M, Ostman-Smith I. Impact of pulse oximetry
screening on the detection of duct dependent congenital heart
disease: a Swedish prospective screening study in 39,821 newborns.
BMJ. 2009 Jan 8;338:a3037.

About Masimo
Masimo (NASDAQ: MASI) is a global leader in
innovative noninvasive monitoring technologies. Our mission is to
improve patient outcomes and reduce the cost of care by taking
noninvasive monitoring to new sites and applications. In 1995, the
company debuted Masimo SET® Measure-through Motion and Low
Perfusion™ pulse oximetry, which has been shown in multiple studies to
significantly reduce false alarms and accurately monitor for true
alarms. Masimo SET® is estimated to be used on more than 100
million patients in leading hospitals and other healthcare settings
around the world. In 2005, Masimo introduced rainbow® Pulse
CO-Oximetry technology, allowing noninvasive and continuous monitoring
of blood constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®),
and more recently, Pleth Variability Index (PVI®) and Oxygen
Reserve Index (ORI™), in addition to SpO2, pulse rate, and
perfusion index (PI). In 2014, Masimo introduced Root®, an
intuitive patient monitoring and connectivity platform with the Masimo
Open Connect™ (MOC-9™) interface. Masimo is also taking an active
leadership role in mHealth with products such as the Radius-7™ wearable
patient monitor and the MightySat™ fingertip pulse oximeter. Additional
information about Masimo and its products may be found at
All published clinical studies on Masimo products can be found at

Forward-Looking Statements
This press release includes
forward-looking statements as defined in Section 27A of the Securities
Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in
connection with the Private Securities Litigation Reform Act of 1995.
These forward-looking statements include, among others, statements
regarding the potential effectiveness of Masimo SET®. These
forward-looking statements are based on current expectations about
future events affecting us and are subject to risks and uncertainties,
all of which are difficult to predict and many of which are beyond our
control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a
result of various risk factors, including, but not limited to: risks
related to our assumptions regarding the repeatability of clinical
results; risks related to our belief that Masimo’s unique noninvasive
measurement technologies, including Masimo SET®, contribute
to positive clinical outcomes and patient safety; risks related to our
belief that Masimo noninvasive medical breakthroughs provide
cost-effective solutions with comparable accuracy and unique advantages,
including: immediate and continuous results that enable earlier
treatment without causing invasive trauma in all patients and in every
clinical situation; as well as other factors discussed in the “Risk
Factors” section of our most recent reports filed with the Securities
and Exchange Commission (“SEC”), which may be obtained for free at the
SEC’s website at
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today’s date. We do not undertake any obligation to update, amend or
clarify these statements or the “Risk Factors” contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.


Irene Paigah, 858-859-7001